Tight regulation of immune responses is not only critical for preventing autoimmune diseases but also for preventing immunopathological damage during infections in which overactive immune responses may be more harmful for the host than the pathogen itself. Regulatory T cells (Tregs) play a critical role in this regulation, which was discovered using the Friend retrovirus (FV) mouse model. Subsequent FV studies revealed basic biological information about Tregs, including their suppressive activity on effector cells as well as the molecular mechanisms of virus-induced Treg expansion. Treg suppression not only limits immunopathology but also prevents complete elimination of pathogens contributing to chronic infections. Therefore, Tregs play a complex role in the pathogenesis of persistent retroviral infections. New therapeutic concepts to reactivate effector T-cell responses in chronic viral infections by manipulating Tregs also came from work with the FV model. This knowledge initiated many studies to characterize the role of Tregs in HIV pathogenesis in humans, where a complex picture is emerging. On one hand, Tregs suppress HIV-specific effector T-cell responses and are themselves targets of infection, but on the other hand, Tregs suppress HIV-induced immune hyperactivation and thus slow the infection of conventional CD4 + T cells and limit immunopathology. In this review, the basic findings from the FV mouse model are put into perspective with clinical and basic research from HIV studies. In addition, the few Treg studies performed in the simian immunodeficiency virus (SIV) monkey model will also be discussed. The review provides a comprehensive picture of the diverse role of Tregs in different retroviral infections and possible therapeutic approaches to treat retroviral chronicity and pathogenesis by manipulating Treg responses.
Mechanisms of Treg expansion and/or accrual during retroviral infection
A critical issue in the study of Tregs is determining the mechanisms by which they become activated and expand during retroviral infections. Defining the molecular mechanisms of virus-induced Treg expansion might pave the way toward developing therapeutics to limit immunosuppressive Treg responses during infection. Such therapeutics might also be used to eliminate persistent infections. Conversely, the knowledge of how viruses induce Treg expansion could be used to therapeutically induce Tregs to treat autoimmune diseases or immunopathogenic responses.
Virus-induced Treg expansion
Because Tregs express a normal T-cell receptor (TCR), it was originally thought that they might simply recognize and respond to viral antigens. That hypothesis, however, could not explain how or why the immune system would recognize one antigen as stimulatory and another as suppressive. In contrast with the theory of pathogen-specific recognition by Tregs, we were unable to demonstrate their presence in FV-infected mice despite many attempts using major histocompatibility complex (MHC) class II tetramers and TCR transgenic FV-specific CD4 + T cells [39, 40] . In fact, FV-specific TCRs are specifically excluded from the Treg repertoire in mice [39, 40] . Instead, FV-induced Tregs display a very broad distribution of TCR variable β (Vß) chain usage, suggesting that they recognize a wide variety of different self-antigens [39] . This is not too surprising because tTregs are generally specific for self-antigens, require continuous antigenic stimulation for survival, and act to preserve self-tolerance [1, [7] [8] [9] . Therefore, tTregs are quite different from conventional CD4 + T cells, which circulate and survive in a naïve state without TCR stimulation. tTregs are distinct from pTregs, which are converted to Foxp3-expressing Tregs from conventional CD4 + T cells in the periphery and may be virus specific [10, 11] . Virus-specific Tregs have been described in a few human infections, including HIV and hepatitis C virus (HCV), but they appear to be so infrequent in those infections that their biological relevance is questionable 
Mechanisms of virus-induced Treg expansion
Two distinct mechanisms of Treg expansion have been defined in the FV model, one IL-2-dependent (Fig 1) and the other IL-2-independent (Fig 2) . Tregs express high levels of the IL-2 receptor (CD25), IL-2 is an essential differentiation factor for Tregs [47] , and it is generally required for Treg function [3] [4] [5] . Therefore, it is not surprising that IL-2 is a required secondary signal involved in the expansion of most FV- A second mechanism of Treg induction, which is self-antigen specific but IL-2-independent, accounts for about 10% of the Treg expansion during FV infection (Fig 2) [39, 50]. Analyses of TCR Vß chain usage showed that a subpopulation of Tregs expressing the Vß5 chain of Tfr, which suppress Tfh necessary for B cell help in germinal centers [99] and subsequent Ab responses [100, 101] , have been the subject of several recent studies [34, 102, 103] . Tfr normally differentiate from tTregs rather than conventional antigen-specific T cells [104] , although exceptions have been observed [105] . The frequency of Tfr in LN is inversely correlated with the frequency of Tfh and germinal center B cells in LN [35, 36] , and also with the avidity of plasma Abs recognizing SIV envelope proteins [35] . Ex vivo HIV infection of human Tfr increased their expression of molecules associated with regulatory activity, namely CTLA- 4, lymphocycte activation gene 3 (LAG-3), GITR, and galectin-3, and also enhanced production of IL-10 and transforming gowth factor β (TGF-β). Consequently, these infected Tfr are very efficient at inhibiting Tfh proliferation and Tfh production of cytokines for B cell help [37] . Similarly, transcriptional analysis of LN Tfr after SIV infection revealed a profile of increased activation [36] . In the same line, HIV-1-infected individuals with broadly neutralizing Abs had a lower frequency of Tregs and a higher frequency of circulating memory Tfh compared with those who did not develop such Abs [106] . This increased response was not specific for HIV antigens because the individuals with broadly neutralizing Abs also had a higher frequency of auto-Abs [106] .
CD4 + T-cell targets

Natural killer cell targets
Natural killer (NK) cells are important innate lymphoctyes that produce proinflammatory cytokines and can kill tumor cells and infected cells following their activation. It has been shown that Tregs indirectly regulate NK cell maturation by restraining IL-2 availability [107] . Therefore, Tregs can regulate the ability of NK cells to react to missing self-antigens on target cells, essentially acting as an IL-2 sink [108] . In a related manner, Tregs regulate NK responses during FV infection. Normally, NK cell responses to acute FV infection are rather weak, and NK cells contribute only marginally to virus control [109] . However, a large part of this impotence is because FV-induced Tregs suppress NK cell proliferation, maturation, and effector cell differentiation during the acute phase of FV infection [110] . Because Tregs express high levels of the high-affinity IL-2 receptor CD25 while NK cells only express the low-affinity IL-2 receptor CD122, Tregs can outcompete NK cells for IL-2 consumption. This lack of IL-2 availability reduces the activation and differentiation of NK cells in FV-infected mice. When Tregs are depleted or IL-2 is experimentally directed to the CD122 receptor of NK cells, full activation of NK cells and significant anti-FV activity are observed. These results indicate that targeted immunotherapy can abrogate the suppression of NK cells by Tregs and enhance virus control. To date, nothing has been published about the influence of Tregs on NK cell responses in HIV-infected humans.
Antigen-presenting cell targets
Tregs also mediate their suppressive action by acting directly on antigen-presenting cells, such as DCs, decreasing DC maturation and subsequently T-cell activation [111] . The formation of Treg-DC conjugates in vivo and in vitro also suggests that DCs may be primary targets of Treg suppression [111] [112] [113] [114] [115] 
Myeloid-derived suppressor cells
Using mice infected with the immunodeficiency-inducing retroviral complex known as LP-BM5, the Green lab demonstrated an increased proportion of both IL-10-producing Tregs and immunosuppressive myeloid-derived suppressor cells (MDSCs) [118] . In adoptive transfer experiments, it was further shown that these two different immunosuppressive cell subsets reciprocally modulated each other's function. MDSCs modulated IL-10 production by Tregs, and in the absence of Tregs, MDSC suppression of T cells was increased.
Effect of HIV infection on Treg functionality
Because Tregs are themselves susceptible to HIV infection (Fig 3) . In contrast, one study reported that productively infected Tregs were less functional on a per cell basis than uninfected, but HIV-exposed, Tregs [122] . Therefore, there may be a different effect from productive infection compared to exposure to defective HIV particles circulating during HIV infection.
Mechanisms of suppression
Knowledge about the molecular mechanisms underlying Treg-mediated suppression of retrovirus-specific T-cell responses is limited. In FV infection, suppression occurs in a direct cellto-cell contact-dependent manner independently of the presence of antigen-presenting cells [72] . Immunosuppressive cytokines such as IL-10 and TGF-β secreted by CD4 + Tregs did not contribute to Treg-mediated immunosuppression in either in vitro or in vivo experiments [67, 72] . Furthermore, Tregs that respond to FV infection do not secrete granzymes, excluding granzyme-mediated killing of effector T cells [123] . This is in line with findings that Tregs inhibit effector T-cell proliferation and function [21] but do not induce apoptosis in T cells during FV infection. The exact mechanism of suppression by Tregs in FV-infected mice is still under investigation. Tregs have been reported to control T-cell activation and proliferation via a contact-dependent mechanism involving cyclic andenosine monophosphate (cAMP) [124] , a mechanism that might also be operative during FV infection. During HIV infection, CTLA-4 (CD152), CD39, and cAMP have been intensively studied as mechanisms of suppression. CTLA-4 coinhibitory molecules are expressed by Tregs from HIV-infected individuals at higher levels than in uninfected individuals [23] . CTLA-4 blockade early during SIV infection of rhesus macaques led to an increase in T-cell activation and viral replication [125] . However, interpretation of these data must be cautious because the Treg role was not specifically addressed in this study. Moreover, Kaufmann et al. showed that Tregs did not play a major part in the in vitro CTLA-4-mediated inhibition of HIV-specific responses because CTLA-4 blockade was still operative in the absence of Tregs and most HIVspecific CTLA-4 + /CD4 + T cells were not Tregs [126] . As mentioned above, cAMP also participates in Treg suppression. Upon stimulation with HIV gp120, human Tregs were shown to accumulate cAMP in their cytosol. Furthermore, the tolerizing effect of HIV gp120 in a xenogeneic graft-versus-host disease model was strictly dependent on the induction of cAMP in human Tregs [64] . In agreement with this hypothesis, Tregs from HIV-1-infected individuals express high levels of intracellular cAMP [127] . We also showed that Treg cAMP was important to control HIV replication in activated effector T cells because suppression was abolished by chemically decreased cAMP levels in Tregs. A similar effect was found in DCs [98] . Blocking gap junction formation between Tregs and effector T cells and inhibiting protein kinase A in effector T cells also abolished Treg suppression, indicating a requirement for cell-to-cell contact [96] .
Treg immunotherapy in lentiviral infections: The pros and cons
Because Tregs can blunt effector immune responses during retroviral infections, it is important to determine whether Treg responses can be manipulated in vivo to overcome suppression and induce immunity. Several approaches have been studied in the FV model. As mentioned earlier, Tregs express GITR, and treatment of mice during acute FV infection using blocking anti-GITR Ab significantly increased virus-specific CD4 + and CD8 + T-cell numbers and function, reduced pathology, and produced long-term increases in CD8 + T-cell functionality [130] . A caveat to this study is that all of the effects could not be attributed to Tregs but might also have been direct activation of the CD8 + T cells. In another study, it was shown that CD8 + T cells could be rendered resistant to Treg-mediated immunosuppression by stimulating them with an agonistic Ab specific for the CD137 (4-1BB) costimulatory molecule [131] . Interestingly, this CD137 agonistic Ab could also be used to reprogram Tregs to become cytotoxic CD4 + T cells with antitumor activity [132] . In those studies, the reprogrammed cells expressed the Tbox transcriptional factor Eomesodermin and granzyme B without loss of Foxp3 expression. Treg responses have also been successfully manipulated to enhance the efficacy of therapeutic vaccines during chronic FV infection. Therapeutic vaccination of chronically FV-infected mice with functionalized calcium phosphate (CaP) nanoparticles temporarily reactivated cytotoxic CD8 + T cells and significantly reduced viral loads [133] . Transient ablation of Tregs during this nanoparticle-based vaccination strongly enhanced antiviral immunity and further decreased chronic viral set points [134] . In the context of HIV infection, Tregs also seem detrimental to the efficacy of therapeutic vaccines [135, 136] , suggesting that adding a Treg blocker along with the vaccine might lead to higher clinical benefit although, to our knowledge, this strategy has not yet been tested. During HIV infection, another exciting prospect is that Treg manipulation could be used to purge the HIV reservoir. In the last 15 years, it has become evident that even the most highly efficient antiretroviral therapy will not cure HIV, due to the persistence of integrated, replication-competent proviruses within host cellular DNA (rev. in [137] ). Therefore, developing "shock and kill" strategies has emerged as a priority in the field of HIV research. The underlying concept of these strategies is that if it were possible to induce viral expression from the latent reservoir, then it might be feasible to trigger immune-mediated clearance of the infected cells through CTLs, NK cells, or immunotoxins. However, a critical limitation of these strategies is that effective and safe latency reversing agents have not yet been identified, and exhaustion of the HIV-and/or SIV-specific CTLs hampers their capacity to properly eliminate reactivated virus (rev. in [137] ). In this context, manipulation of Treg numbers and/or functions could be advantageous, based on the results of Treg depletion in simian models. Indeed, as mentioned above, transiently decreasing Treg numbers by Ontak treatment led to both reactivation of latent HIV and boosted SIV-specific CD8 + T-cell frequencies in virally suppressed rhesus macaques. The result was rapid clearance of the reactivated virus [80], thus achieving both goals of the "shock and kill" approach at the same time. This treatment was safe, without signs of untoward autoimmune disease ([80] and 2017 discussion between Drs Apetrei, Pandrea, and Chougnet). Transient Treg ablation might be more efficacious in this context than the manipulation of Treg function because Tregs themselves have been suggested to be a reservoir for latent HIV [138, 139] , although that has not been confirmed by all studies [140] . Of note, in an HIV-infected patient being treated for melanoma with Ipilimumab, an anti-CTLA-4 Ab known to effect Tregs, transient decreases in HIV-1 RNA were detected following infusions of the Ab [141] . Besides HIV, Treg-mediated suppression of antiviral effector cells is a matter of concern in other chronic virus infections such as HCV, hepatitis B virus (HBV), human papillomavirus (HPV), and Epstein-Barr virus (EBV) [74] and limits responses to therapeutic vaccines in patients infected by these chronic viruses. Notably, patients with large lesions due to HPVinduced vulvar intraepithelial neoplasia also had high frequencies of HPV-specific CD4 + / CD25 + /Foxp3 + T cells and displayed a lower HPV-specific interferon γ (IFNγ)/IL-10 ratio after therapeutic vaccination [142] . Therefore, therapeutic manipulation of Tregs to reactivate or enhance virus-specific immunity and subsequently reduce chronic infection levels could have widespread clinical applications.
In considering therapeutic manipulation of Tregs, the Janus nature of Tregs during HIV infection should not be forgotten. Tregs limit generalized immune activation during HIV infection [92] [93] [94] , and in the era of suppressive HAART, persistence of immune activation is highly associated with the noninfectious causes of HIV-driven increased mortality (rev. in [143] and [144] ). Relevant to this concept, low Treg frequency in HIV elite controllers is strongly associated not only with immune activation but also with accelerated atherosclerosis and other morbidities linked to inflammation [145, 146] . Therefore, depletion or ablation of Treg function to boost immune responses or purge the reservoir may end up producing deleterious consequences. In this context, increasing Treg frequency could be beneficial to HIV patients because Tregs limit atherosclerosis (rev. in [147, 148] ). The ongoing statin clinical trials in HAART-treated patients will be informative in this context. Statins are given to HAART-treated patients, including normolipidemic patients (REPRIEVE Phase IV clinical trial), with the goal of decreasing HIV-associated cardiovascular risk. Importantly, we and others have shown that statin treatment increases Treg frequency [149, 150] , which likely contributes to their pleiotropic anti-inflammatory properties. Analysis of Treg dynamics in statintreated HIV-infected patients, in relation to immune activation and clinical outcome, may provide important information about the exact role of Tregs in HIV infection.
Conclusions
Given the complex roles that Tregs play in retroviral and other infectious diseases, the successful application of therapeutics to treat infectious diseases via modulation of Tregs will obviously require extremely detailed information regarding both the positive and negative contributions of Tregs in a particular infection. We now know that the balance of beneficial versus detrimental effects from Tregs can change during the course of a retroviral infection, especially between the acute and chronic phase of infection. Therefore, it is important to recognize not only which infectious agent induced the Treg response but also the phase of the infection. The discovery of molecular mechanisms that initiate and control Treg responses in infectious diseases is key to the understanding and manipulation of these complex processes. For example, the presence of endogenous retroviruses that express specific antigens may strongly affect individual Treg responses. We also know that virus-induced Tregs alter not only the response against the virus that initiated the response but also subsequent responses to other infections. Therefore, the patient's history of infections can affect the homeostatic level of Treg-mediated suppression. Numerous other factors that need further study may also play important roles in Treg responses, including sex, age, underlying medical conditions, drug use, stress, etc. It is extremely important that further investigations continue to delineate the important factors influencing the impact of Tregs on both pathology and antiviral immunity in retroviral infections so that personalized medicine can be developed. 
